Sanofi filed a lawsuit against Eli Lilly accusing the company of infringing seven patents related to insulin and delivery devices. According to a Reuters article, Sanofi is seeking to halt Lilly's proposed commercial marketing in the United States of a rival treatment to Sanofi's Lantus, known as Abasria, saying the sale would violate its rights.
Lilly spokeswoman Tammy Hull said the Indianapolis-based company is reviewing Sanofi's latest lawsuit, and "does not believe the application infringes any of the asserted patents." Read the full story